Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Why investors should stay sweet on Tate & Lyle

A souring of sentiment towards Tate & Lyle (TATE) is an opportunity for value investors to take a taste of the international business.
Recent earnings downgrades reflect year-to-date dollar weakness and margin pressure amid investment in the business. This has weighed on the equity valuation.
But Tate & Lyle is on the path of a sustained recovery and has a positive catalyst in the promotion of CFO Nick Hampton to CEO, providing the prospect of a renewed strategy to accelerate the £2.62bn cap’s transformation to a speciality ingredients play.
SPLENDID POTENTIAL
Tate’s two divisions are the relatively commoditised Bulk Ingredients unit, selling bulk sweeteners and industrial starches, and Speciality Food Ingredients (SFI), the long-term growth driver, whose products span texturants such as starch and gums, sweeteners, comprising nutritive sweeteners and no-calorie sweeteners including ‘SPLENDA Sucralose’.
Following a testing few years of transformation towards a higher margin, less volatile speciality ingredients supplier, Tate is in a far healthier position operationally.
However, its third quarter update (8 Feb) was harshly punished. Though it reiterated profit guidance for the year to March 2018, management cautioned that investments behind the longer term development of the SFI business ‘will moderate profit growth in the second half’.
TATE’S TOO CHEAP
As Investec Securities explains in its latest note (12 Feb), ‘we appreciate there is a degree of investor fatigue with the multi-year SFI strategy not yet delivering the hoped-for benefits. But, Tate is now VERY cheap and new management may well offer better ideas for value creation.’
The broker reiterates its ‘buy’ rating on valuation grounds and a 735p price target implying 29.5% upside. Significantly, Investec’s 903p sum-of-the-parts valuation is almost 60% higher than the current battered share price.
We think Tate & Lyle is oversold. For the year to March 2018, Investec still forecasts an increase in normalised pre-tax profit to £302.3m (2017: £271m) for earnings of 49.3p and a 28.6p (2017: 28p) dividend, ahead of pre-tax profit of £305m, 49.8p of EPS and a 28.8p shareholder reward for March 2019.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Big News
- Why interest rates on deposit accounts could be set to rise
- Get ready for major changes to the FTSE 100 and FTSE 250 at next week’s reshuffle
- Crunch time as Tesco’s acquisition of Booker goes to shareholder vote
- Four important stories from the past week: HSBC, BHP Billiton, Acacia Mining and Fidessa
- Can airlines avoid a repeat of the recent ticket price war?